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Introduction
Survival analysis is a statistical approach to evaluate an event 
or study where the outcome is based on the vital status of the 
samples.1 Cancer treatment and clinical trials are two common 
use cases for analyzing the survival of the samples based on 
the given treatment. However, over the recent years, several 
major web servers that calculate the survival contribution of 
mRNAs by employing publicly available clinically annotated 
breast cancer microarray data have become available including 
Kaplan–Meier plotter,2 GOBO,3 RecurrenceOnline,4 and bc-
GenExMiner.5 PrognoScan6 is one of the first studies integrat-
ing microarray expression data from Gene Expression Omnibus 
(GEO) for multiple cancer types to predict the prognostic 
mRNAs. As a result of increase in the availability of sequenc-
ing-based genomic data along with clinical annotations across 
cancer types from various consortiums such as The Cancer 
Genome Atlas (TCGA)7–9 (http://cancergenome.nih.gov/) 
and the International Cancer Genome Consortium (ICGC) 
(https://icgc.org/), cancer prognostic biomarker identification 
and comparison among them has become the major outcomes 
of various multi-omic studies. SurvExpress10 and PROGgene11 
have integrated multiple RNA sequencing (RNA-seq) expres-
sion profiles from GEO datasets and report the contribution of 
an mRNA expression as a prognostic biomarker. SurvNet12 is 
an online service for identifying the network-based biomark-
ers associated with clinical information. It is preloaded with 
TCGA data and reports the survival significance in mRNA 
and protein levels. cBioPortal13 is a comprehensive web-based 
platform that integrates several cancer genomic datasets includ-
ing those from TCGA. However, all of the listed services only 
report the prognostic properties and survival contribution at 
mRNA level. Alternative splicing is a posttranscriptional gene 
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regulatory mechanism that contributes to different protein 
products due to alterations in the combination of exons origi-
nating from the same gene.14 Exon inclusion/skipping is a class 
of a splicing event, wherein an exon is included or missed in 
the final isoform product.14 Hence, identifying the potential 
prognostically involved/missed exons in cancer genomes would 
be beneficial for a better understanding of not only the involve-
ment of posttranscriptional regulatory alterations in cancers 
but would also provide novel insights into potential exon-level 
functions in tumor evolution. For example, SRSF2, an RNA-
binding protein, mutations drive recurrent mis-splicing of key 
hematopoietic regulators such as EZH2 in patients with myel-
odysplastic syndromes.15 Similarly, mutant U2AF1, an RNA-
binding factor, alters downstream gene isoform expression by 
altering the splicing mechanism.15 A recent study16 analyzed 
genome-wide patterns of RNA splicing across 805 matched 
tumor and normal control samples from 16 distinct cancer 
types to identify signals of abnormal cancer-associated splic-
ing. This study reports intron retention, a category of alterna-
tive splicing, to be common across cancers even in the absence 
of mutations directly affecting the RNA splicing machinery. In 
light of several recent studies providing support for extensive 
rewiring of posttranscriptional regulatory networks in multiple 
cancer types,16–19 there is an immediate need for resources that 
can enable rapid mining and validation of high-confident prog-
nostic alternative splicing events in cancer transcriptomes.
In this study, we present ExSurv (https://exsurv.soic.
iupui.edu/), which to our knowledge is the first online web 
server that provides exon-level survival significance by using 
the RNA-seq expression datasets and the associated clini-
cal metadata for four cancer types from the TCGA project7,9 
(http://cancergenome.nih.gov/). We precalculated the prog-
nostic significance of more than 600,000 annotated exons in 
Ensembl20 using survival package21 in R across the four can-
cer types. We stored the TCGA clinical data, exon survival 
P-values, and the expression of significant exons, for visu-
alizing the survival curves per exon in a MySQL database. 
A PHP/R backend and a JavaScript frontend were employed 
for designing the interface and calling R visualization libraries. 
We also compare the overlap in the prognostic exons and their 
functional overlap across cancer types studied here.
Materials and Methods
cancer types and the corresponding number of can-
cer samples analyzed in this study from the tcGA project. 
We selected four cancer types, namely, breast invasive carci-
noma (BRCA), liver hepatocellular carcinoma (LIHC), glio-
blastoma (GBM), and kidney renal papillary cell carcinoma 
(KIRP), and quantified the exon expression levels for patients 
with accessible raw RNA-seq data. It is important to note 
that TCGA is a collaborative effort; hence, the generated data 
could be from different dates and platforms. However, it is not 
suggested to do batch effect correction since it may bring addi-
tional noises to the analysis. The majority of TCGA cancer 
patients are White males (except breast cancer patients) and 
aged from 40 to 80 years at the time of first time cancer diag-
nosis (see Table 1). While there are several clinical features 
available for each cancer type, to simplify the calculations and 
increase the performance of the web server given the large 
number of annotated human exons employed in the analysis, 
we only considered the prognostic effect of exons among all 
the samples of a cancer type without controlling for covari-
ates such as gender, age, or grade for a given cancer type. It 
is important to note that most existing web servers perform-
ing survival analysis for multiple cancer types also employ a 
similar approach to avoid sample size artifacts when multiple 
covariates are considered.
workflow for processing rNA-seq data and quantifi-
cation of exonic expression levels. Hierarchical indexing for 
spliced alignment of transcripts (HISAT)22 is a highly effi-
cient alignment tool for aligning short reads from RNA-seq 
experiments onto reference genome. HISAT claims to be the 
fastest alignment system currently available, with better accu-
racy than most other methods. We ran HISAT with – dta 
parameter options to align each of the RNA-seq samples to 
generate corresponding Binary Alignment/Map (BAM) files 
using the human genome reference 38 annotations obtained 
from Ensembl.23 We then quantified the expression of exons 
using StringTie,24 a computational method that applies a net-
work flow algorithm together with optional de novo assembly, 
and estimated the multimap corrected number of reads for 
every annotated exon in human genome build 38. To normal-
ize the number of reads mapped to genomic regions, transcript 
per million is proposed by Li and Dewey,25 which corresponds 
to normalized read count value based on the length of the 
transcript isoform under consideration and the total number 
of mapped reads in the whole genome. We employed a similar 
approach to quantify the exon expression, normalized by the 
length of exon and the total number of the reads mapped to the 
whole genome. Here, E(xi) is the expression of ith exon. C and 
L functions for an exon represent the number of multimap 
corrected reads mapping to the exon and length of the exon, 
respectively, across the complete transcriptome of a sample.
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clinical metadata from tcGA samples employed 
for survival analysis in exsurv. Clinical data are crucial 
for survival analysis. TCGA (http://cancergenome.nih.gov/) 
provides both sequencing data and the corresponding clinical 
information for most of the patients for each cancer type 
included in ExSurv. The clinical data included the vital status 
of a patient, number of days from the first day of medication 
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construction of the database backend for serving 
the user interface of exsurv. We aligned the raw RNA-seq 
datasets from the cancer samples against HG38 and used the 
exon annotations from Ensembl database,23 as discussed above. 
The exon survival information and metadata associated with 
cancer patients were organized into separated tables. Likewise, 
the genomic annotations were organized into separate tables 
(Supplementary Fig. 1 for a schema of the ExSurv database). 
The design of the database enables updating either the anno-
tations or precomputed datasets or both without extensive 
dependencies, thereby speeding up updates to the ExSurv 
when there are changes in the datasets without the need for a 
structural change in the database. We stored the data required 
for our service in a MySQL database. We also developed PHP 
scripts to handle user queries and generate exon-level survival 
plots by integrating preprocessed data from the database to 
perform dynamic survival analysis using the queried data in R 
with survival package.26
Framework employed for building the user interface 
of exsurv. We implemented a simple interface for users to 
search for their gene of interest and visualize the exon-level 
survival analysis results in the selected cancer type. We use 
JavaScript integrated with PHP scripts to query the database 
and retrieve the expression results that are then provided as 
input for survival analysis in R. ExSurv provides the users 
to not only search for genes of interest and naturally all the 
exons associated with it but to also limit to certain level of 
significance. The results of the search are listed as survival 
plots for each exon corresponding to the gene that matches 
the query (eg, a gene symbol or Ensembl gene ID). The meta-
data related to that exon in the context of the cancer samples 
analyzed is also given next to its survival plot. The users can 
export the exon-level survival plots for storing them locally. 
We also implemented an export functionality for downloading 
Table 1. number of cancer patient samples employed for each cancer type in exsurv.
CANCER NUMbER of ANALYzED 
SAMPLES 
NUMbER of PATIENTS 
WITH CLINICAL DATA
GENDER 
(M/f)
RACE AGE
Breast invasive carcinoma (BrCa) 1040 1099 12/1087 W:758
B:183
a:61
.80: 55
60–80: 438
40–60: 508
,40: 98
Glioblastoma (GBm) 174 594 365/229 W:505
B:51
a:13
.80: 22
60–80: 246
40–60: 249
,40: 70
Kidney renal papillary cell carcinoma (KIrP) 287 287 211/76 W:207
B:61
a:5
.80: 14
60–80: 138
40–60: 119
,40: 16
Liver hepatocellular carcinoma (LIHC) 368 368 250/118 W:180
B:17
a:160
.80: 10
60–80: 184
40–60: 143
,40: 27
Notes: other clinical parameters and the corresponding composition of the cancer cohorts are shown. We also categorized the age of patients into four categories 
with intervals of 20 years for reference.
Abbreviations: (race column represents) W, White; B, Black; a, asian.
till the last follow-up, gender, cancer subtypes, and other 
cancer-specific information. We included vital status and the 
number of days since last follow-up in our survival analysis.
survival analysis for exons to identify prognostic 
markers in a cancer type. We employed survival package in 
R26,27 to estimate the contribution of a given exon to survival 
of patients in a cancer type based on their expression. We 
divided the cancer patients based on the expression of a given 
exon into two groups (ie, High and Low). The group that was 
labeled as High are the patients where the expression of the 
exon is above the median expression of the same exon among 
all the specific cancer type patients. Similarly, we labeled the 
patients Low if the expression of the exon is below the median 
expression level of that exon, among all the patients studied in 
a cancer type. We applied Kaplan–Meier estimate of survival 
with log-rank test and Cox proportional regression model to 
measure the significance of difference between the High and 
Low groups in a given cancer type. To increase the stringency 
and to reduce the potential false positives, we introduced an 
additional approach by redefining the High group as patients 
where the expression of an exon is more than the third quartile 
expression of the same exon, among all the specific cancer 
types, and Low group if the expression of the exon is less than 
the first quartile expression level of that exon, among all the 
patients studied in a cancer type. We applied similar statistical 
models to evaluate the survival contribution of the exons in 
every cancer type. We corrected the results for the false dis-
covery rate (FDR) using Benjamini–Hochberg procedure. The 
exons that exhibited a survival probability of at least 0.05 as 
a result of the test were considered as significant prognostic 
biomarkers for downstream analysis, and the corresponding 
FDR values are also provided as output on the web server for 
each exon and the same results are available in the MySQL 
dump for local use.
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raw expression data as well as the associated metadata across 
cancer samples analyzed for each exon. ExSurv does not 
require users to log in, and it is freely available on https://
exsurv.soic.iupui.edu/.
results and discussion
overview of datasets and approach employed for building 
exsurv. Figure 1 shows the major steps involved in the genera-
tion of exon-level survival estimates as implemented in ExSurv 
database and visualization engine. Briefly, we obtained the raw 
RNA-seq datasets for individual patients from CGHub portal 
(https://cghub.ucsc.edu/) after an approval process from the 
dbGaP (http://dbgap.ncbi.nlm.nih.gov/) to access the raw 
datasets for various cancer types. Grouping of the patients 
based on exon levels together with the vital information of 
the patients and the time-to-event information for each can-
cer type were used for survival modeling by employing the 
Kaplan–Meier estimate with log-rank test (see “Materials 
and methods” section). Resulting datasets were stored in 
a MySQL database as described below and a visualization 
engine built for dynamic access to the underlying data.
Four tables were designed to store the gene–transcript–exon 
relationship (Supplementary Fig. 1). “Gene” table has Ensembl 
gene IDs, their corresponding symbols, and gene synonyms to 
facilitate searches when users query for alternate gene names in 
addition to those reported as standard HUGO Gene Nomen-
clature Committee (HGNC) gene symbols (http://www.gene-
names.org/). “Transcript” and “Transcript_Exon” tables show 
the transcript IDs associated with each gene and exons that are 
associated with each transcript, respectively. Since exons are the 
building blocks of ExSurv, their genomic coordinates, associ-
ated chromosomes, and strand information are organized in 
the “Exon_Info” table that is connected with the “Transcript_
Exon” table. “Cancer_Patient_Info” table stores the clinical 
information retrieved from TCGA portal such as vital status, 
number of days from the first day of medication till the last 
follow-up, and gender for all the patients analyzed in this study 
for each cancer type. Table 1 shows the composition and the 
Download raw RNA-
seq reads from
dbGaP for 4 cancer
types  
Align the reads
against HG38 using
HISAT  
Quantify exon
expression for
annotated HG38
exons using
String Tie
Group exons into high and low
expressed based on their median
expression for each cancer type
Import metadata and preprocessed
data into a MySQL database
Develop a web server for querying
the database, doing survival
analysis and visualizing results 
Compute the significance between
the groups for each cancer type
using Kaplan-Meier estimate of
survival with Log-Rank test in
survival package in R
figure 1. major steps involved in the generation of exon-level survival estimates in the exsurv database and visualization engine. as outlined in the 
flowchart, our analysis pipeline comprises obtaining the raw RNA-seq datasets for more than 1800 patients spanning four different cancer types along 
with their clinical metadata. raw rna-seq was processed using HIsat22 aligner to generate BAM formatted files, and StringTie24 was used for exon-
level expression quantification. Exon expression level across patients in a given cancer type along with clinical information on the follow-up time periods 
were used to generate Kaplan–meier plots and corresponding P-values from log-rank tests. a mysQL database was developed to store the exon-level 
expression as well as the results of the survival analysis to facilitate dynamic querying and dissemination of the data. a web server was developed to 
show the Kaplan–meier plots and corresponding expression data employed for generating them.
ExSurv
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number of patients with various clinical attributes for the four 
cancer cohorts employed in this study. We stored the precalcu-
lated survival probability of each exon across every cancer type 
in “Cancer_Exon_Survival” table. “Exon_ Survival_Data” con-
tains the generated expression data for each exon along with 
its corresponding expression group, needed for survival analysis 
and for generating the survival plots (Supplementary Fig. 1 for 
the complete database schema).
exsurv provides a rapid means of visualizing the exon-
level survival contributions for all exons in a given gene. 
ExSurv has a user friendly web interface for querying and visu-
alizing the exon-level survival contributions for all exons asso-
ciated with a given gene symbol or Ensembl gene ID. It has 
a search form placed next to its main navigation bar to make 
it accessible from everywhere, and the form includes P-value 
threshold and cancer name selection for narrowing down the 
query (Fig. 2A). When a search request is received by ExSurv, 
it queries the database for matching exons to the given gene 
and the exons that are significant under a given P-value thresh-
old and are detected in a given cancer type. If any exon is avail-
able for visualization, the survival plots for each of them are 
prepared using survival package in R and returned to the user 
as portable network graphics (PNG) formatted images, which 
are supported by all browsers. Generated plots along with the 
identifiers such as exon ID, transcript ID, gene ID, and gene 
symbol, as well as P-value, are provided as a resulting table 
(Fig. 2B). Each plot can be exported as resolution-independent 
scalable vector graphics (SVG) images. Moreover, the raw data 
used to generate the visualization of the survival plots can be 
exported as a table in Tab-Separated Values (TSV) format. 
These export options are given in the results table under 
“Export” column.
Most prognostic exons are cancer specific. We extracted 
the high-confident prognostic exon biomarkers across each of 
the cancer types studied here at a survival probability ,0.01 to 
study their overlap across cancer types. A comparison of the 
prognostic exons revealed that while more than 40,000 exons 
were significant for BRCA, only 4000–7000 significant exons 
were found for other cancer types. This can be due to a number 
of reasons including the variability in the sample sizes such as 
the higher coverage for BRCA compared to the other cancer 
types and heterogeneity in the cancer samples for all cancer 
types may not be the same. Nevertheless, a comparison of the 
number of exons, which were found to be significant across 
two or more cancer types, clearly revealed a surprising trend 
(Fig. 3). We calculated the pairwise significance of the overlap 
among the cancers using hypergeometric test and found that 
the reported overlap values between all the pairs are indeed 
signi ficant (P-value , 0.01). We found that only a small frac-
tion of the exons were shared among different cancer types. 
One might argue that the primary reason for observing cancer-
specific prognostic exons is due to the difference in tissue of ori-
gin. To further validate this hypothesis, we analyzed the overlap 
between KIRP and kidney renal clear cell carcinoma (KIRC) 
to verify that cancers originated from the same anatomical con-
text would also exhibit small overlap; hence, the origin of the 
dissimilarity between the set of prognostic exons is indeed not 
associated with tissue of origin rather it is related to cancer-
specific mechanism. The analysis suggests that there is indeed 
small overlap between the two cancer types (hypergeometric, 
figure 2. screenshots from exsurv user interface. (A) the search box with a text box for gene symbol or ensembl gene ID entry, P-value text box that 
defaults to 0.05 and cancer name select box. (b) A sample results table that shows the first two exons obtained. Identifiers are linked to their sources such 
as Ensembl and GeneCards, and the survival plot can be zoomed in by clicking it. The first button under “Export” column for exporting the survival plot as 
SVG file and the second one is for exporting a matrix of expression levels of the exons across the patient cohort of a cancer along with several available 
metadata variables for the patient group as TSV file.
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P-value ,0.001) (Supplementary Fig. 2). This observation 
suggests that most prognostic exons are likely to be cancer spe-
cific, indicating a potential for extensive differences in the post-
transcriptional alterations seen across cancer types.
Functional analysis of genes associated with survival-
associated exons reveals unique as well core functional signa-
tures of cancer types. Performing a functional analysis of the 
prognostic exons against the current literature is not yet possible 
as very few studies have attempted to analyze the exon-level 
contributions to cell growth phenotypes. However, it is possible 
to analyze the genes associated with the prognostic exons, and 
hence, we extracted the list of top 500 genes with highest num-
ber of prognostic exons, contributing to patients’ survival in each 
cancer type to understand the biological processes associated with 
such exons. Figure 4 shows the analysis of the enriched biologi-
cal processes associated with the extracted genes for each cancer 
type using ClueGO28 against Gene Ontology database29 with a 
P-value ,0.01. Extracted biological processes suggest that exons 
figure 3. Venn diagram showing the number of prognostic exons 
in four different cancer types. Significant majority of the exons 
contributing to patients’ survival were found to be cancer specific. Only 
exons that were found to be significant at a P-value threshold of 0.05 
from the log-rank test were included in this plot. at these thresholds, 
no exons were found to be significant for prognosis in all the cancer 
types studied here.
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figure 4. Functional enrichment using ClueGO for genes associated with exons found to be significant in (A) BrCa, (b) LIHC, (C) KIrP, and (D) GBm. 
Biological terms are represented as nodes, and the size of a node is defined based on the number of overlapping genes and the significance of 
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contributing to GBM patients’ survival are involved in extracel-
lular matrix organization and regulation of protein transport 
(Fig. 4D). In contrast, prognostic exons in breast cancer patients 
are primarily active in critical cell functions such as intracellular 
and cytoplasmic transport, organelle and chromosome organiza-
tion, mitotic cell cycle, response to stress, protein localization to 
organelle, and posttranscriptional regulation of gene expression 
(Fig. 4A and Supplementary Fig. 3). In KIRP patients, survival-
associated exons were found to be enriched for cellular respira-
tion, oxidation–reduction process, and fatty acid beta-oxidation, 
perhaps indicating kidney-specific alterations. Similarly, oxoacid 
and organic acid metabolic processes together with cell–cell 
adhesion processes were enriched in liver cancer with promi-
nent contribution of immune response-related pathways such as 
T-cell activation and aggregation, which are already documented 
to be implicated in liver disorders (see Fig. 4, Supplementary 
Fig. 3, and Supplementary Table 1).30 We also performed func-
tional enrichment analysis of genes whose exons are signifi-
cantly contributing to patients’ survival in at least two cancer 
types. These results suggest that cell adhesion, carboxylic and 
fatty acid metabolic process, and positive regulation of T-cell 
signaling pathway are few major biological processes that were 
enriched among the significant exons associated with KIRP, 
LIHC, and BRCA (P-value ,0.05; Supplementary Fig. 4).
conclusions
Cancer is a complex multifactorial disease with our under-
standing of the posttranscriptional mechanisms contributing 
to or causal to the cancer phenotypes being very limited. Most 
approaches currently focus on identifying prognostic markers 
at the individual gene or transcript level within a cancer type or 
across cancer types; however, our understanding of the post-
transcriptional mechanisms altered in cancer transcriptomes 
or the resulting splicing biomarkers are limited. Hence, iden-
tifying and understanding the function of cancer type-specific 
prognostic biomarkers based on such poorly characterized lay-
ers of regulation is challenging and has recently gained lot of 
attention in precision medicine field. Alternative splicing is a 
posttranscriptional mechanism that might change the expres-
sion level of the resulting mRNA isoform and hence the final 
protein product consequently, thereby causing aberrations in 
the downstream interactome and disease phenotypes. In par-
ticular, exon inclusion/exclusion is one of the well-studied 
alternative splice forms that results in different protein prod-
ucts. While a complete and comprehensive understanding of 
the functions of exons in the context of their corresponding 
functional transcripts is still premature, with the availability 
of novel CRISPR/Cas9 genome editing screens, it might be 
increasingly possible to study the impact of individual exons on 
cancer phenotypes in order to rationally design exon-specific 
therapeutics to decrease the off-target effects and to increase 
specificity towards more personalized treatment options for 
cancers. To address this gap and to provide a platform for 
rational identification of prognostic exons, in this study, we 
developed ExSurv, a database and web server for exon-level 
survival significance for four cancer types. ExSurv is a web-
based platform where a user can query a gene of interest in a 
cancer type, resulting in the expression levels of all the exons 
associated with the gene along with their survival significance 
and associated plots to be visualized online or for local use.
Our analysis of the resulting prognostic exons across four 
cancer types clearly revealed that most of the survival-asso-
ciated exons are unique to a cancer type with few associated 
processes common across cancer types, possibly suggesting 
significant differences in the posttranscriptional regulatory 
pathways contributing to prognosis. ExSurv is a fully func-
tional proof-of-concept platform that will be improved by 
adding additional cancer types and other functionalities in 
future versions. Current version of ExSurv performs the sur-
vival analysis of exons among the patients of a selected cancer 
type without employing additional clinical features such as 
gender and subtype. We will also improve the current plat-
form to facilitate exon survival analysis only among patients 
who match specific clinical features. Currently, such filtering 
frequently limits the number of samples, thereby decreasing 
the power of the analysis for most cancer types. In addition, 
RNA-seq data for most of the cancer types from TCGA proj-
ect have been sequenced from multiple sequencing centers or 
platforms, which could potentially add batch effects to the 
downstream analysis. However, since such postprocessing and 
stratification can further reduce the power of the data, care-
ful considerations should be included in the pipelines. This 
becomes especially important as the number, source, and het-
erogeneity of the samples increase due to contributions from 
initiatives such as the ICGC.31 We anticipate that future ver-
sions of ExSurv, which can accommodate such stratifications 
and controls, could serve to become very powerful for studying 
the impact of prognostic exons even in subtypes of cancers.
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supplementary Material
supplementary table 1. List of GO terms significantly 
associated with single or a pair of cancer types (P-value ,0.01). 
GO associations are extracted from the latest Gene Ontology 
database using ClueGO and results are ordered by P-value.
supplementary Figure 1. The database schema of 
Exsurv: Genomic annotations from ENSEMBL are stored 
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in Gene, Transcript, Exon_Info, and Transcript_Exon tables. 
This enables the updating of annotations without changing 
the whole database structure. Patients’ clinical information 
are stored in Cancer_Patient_Info. Precomputed survival sig-
nificance values and the exon expression values required for 
survival plots are stored in Cancer_Exon_Survival and Exon_
Survival_Data, respectively.
supplementary Figure 2. Prognostic exons in kidney 
renal papillary cell carcinoma (KIRP) and kidney renal clear 
cell carcinoma (KIRC) exhibit small but significant overlap 
(P-value ,0.001).
supplementary Figure 3. Pie charts for each cancer type 
shows the relative significance of GO terms among the associ-
ated genes. Bigger pie implies a higher significance GO term 
related to the cancer genes compared to other terms.
supplementary Figure 4. Functional enrichment analysis 
using ClueGO for genes associated with exons found to be sig-
nificant in at least two cancer types. Carboxylic acid metabolic 
process and positive regulation of T-cell receptor signaling 
pathway are two major pathways enriched in the gene sets.
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